Drug Discovery Today
MAY 26, 2022
‘GMC Life Sciences Fund by Praetura’ aims to bolster Greater Manchester and Cheshire and Warrington’s flourishing life sciences sector. The fund, raised by partners including Bruntwood SciTech, Greater Manchester Combined Authority (GMCA) and Cheshire and Warrington Local Enterprise Partnership (LEP), will be deployed by Manchester-based Praetura Ventures.
Drug Patent Watch
MAY 2, 2022
DrugPatentWatch has been named to Genetic Engineering News‘ Best of the Web list. The review by Genetic Engineering News profile highlighted the “new training modules designed to help you find…. The post DrugPatentWatch named “Best of the Web” by Genetic Engineering News appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
MAY 24, 2022
A few weeks ago, GoodRx surprised investors with the unpleasant news that a major grocery chain had stopped accepting its discount card for an unspecified number of prescriptions. As I explain below, the unnamed chain appears to be Kroger— the sixth-largest U.S. pharmacy. What’s more, GoodRx disclosed that Kroger accounts for an unexpected one-quarter of its prescription business.
The Pharma Data
MAY 31, 2022
BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s disease Phase 2b LUMA to enroll approximately 640 participants with early-stage Parkinson’s disease; most advanced clinical study of a LRRK2 inhibitor. Denali Therapeutics Inc. (NASDAQ: DNLI), and Biogen Inc. (NASDAQ:BIIB) today announced that dosing has commenced in the global Phase 2b LUMA study to evaluate the efficacy and safety of BIIB122 (DNL151), as
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The Open Targets Blog
MAY 31, 2022
Lorenzo Bomba was a postdoctoral fellow in the Soranzo group, which uses large-scale genomic analysis to study the human variation linked to cardiometabolic traits and diseases. He recently published the results of an Open Targets project which found new associations between genes and blood metabolites in the American Journal of Human Genetics.
Altus Drug Development
MAY 31, 2022
From natural health products to life-saving medicines, all pharmaceutical products must undergo an analytical method development process. Through analytical method development, validation, and transfer, drug development and manufacturing are kept safe, efficient, and compliant with the law. What is analytical method development? Analytical method development is the creation of a set of experimental conditions to perform analytical procedures in chemical samples.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
MAY 18, 2022
Annual Drug Patent Expirations for DUZALLO Duzallo is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are nine patents protecting this drug. DUZALLO drug…. The post New patent for Ironwood Pharms drug DUZALLO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
MAY 20, 2022
Today’s guest post comes from Jane Barlow, Chief Clinical Officer, and Susan Raiola, President of Real Endpoints. Jane and Susan discuss the mechanism and benefits of warranties in the realm of value-based contracts. To learn more about payer-pharma warranty contracts and whether these agreements can solve issues that limit the utility of more traditional value-based contracts, sign up for Real Endpoints’ free June 9 webinar: Putting Innovative Contracts Under Warranty.
The Pharma Data
MAY 31, 2022
Study Showed Significant, Sustained Reduction in Lipoprotein(a) During Treatment Period. Lipoprotein(a) Reduction was Consistent With Phase 1 Results. Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD).
Translation
MAY 27, 2022
Thanks to a spotlight from the Covid-19 pandemic, the biotechnology industry attracted record investment in 2020 and 2021. But maintaining that edge will require building more talent and improving commercial development and execution, according to McKinsey. One competitive differentiator: deepening relationships between academia and industry. This June’s BIO International Convention in San Diego is crammed with 100+ sessions in just four days.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Altus Drug Development
MAY 31, 2022
Everyone is interested in having access to the best healthcare available. However, many patients end up having to face the fact that many treatments are unfeasible, too expensive, or potentially counter-conducive. Knowledge of issues within the healthcare system is not unknown to those in charge. However, dealing with them often requires making structural changes many industry players are not willing or able to perform.
Drug Discovery Today
MAY 31, 2022
Talk from Roche engineer Tiffany McIntire will highlightopportunities for the pharma sector to reinvent packaging to bemore focused on patient needs in areas such as medication takenorally
Drug Patent Watch
MAY 9, 2022
Annual Drug Patent Expirations for TARGINIQ Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are fifteen patents protecting this drug. Drug patent…. The post New patent expiration for Purdue Pharma drug TARGINIQ appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
MAY 17, 2022
Two weeks ago, Paula and I had the pleasure of attending Asembia’s 2022 Specialty Pharmacy Summit at the wonderful Wynn Las Vegas. Below, I violate Vegas code and tell you what happened there. I offer reflections on my keynote session with Scott Gottlieb, share my experiences during the featured session, and highlight three crucial specialty industry trends.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Pharma Data
MAY 31, 2022
– Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance and commercial activities for Spikevax TM from 1st August 2022 – Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period.
Creative Biolabs
MAY 25, 2022
Cancer has become the second largest health threat in the world, with about 10 million people dying of cancer in 2020. For decades, cytotoxic-based chemotherapy has been the main treatment for all kinds of cancers. These cytotoxic drugs include DNA base analogs, antimetabolic drugs, tubulin inhibitors, etc. However, most of these chemotherapeutic drugs show a low therapeutic index, and serious side effects are usually attributed to the exposure of non-specific drugs to off-target tissues.
ProRelix Research
MAY 26, 2022
The United States has always been and remains to be the leading place for the conduct of clinical trials. According to Clinicaltrials.gov, the largest clinical trials registry, 32% of registered […]. The post Planning Clinical Trial in USA? Here is what you should know appeared first on ProRelix Research.
Drug Discovery Today
MAY 27, 2022
Medicines Discovery Catapult (MDC) is hosting UK SPINE, ‘Healthspan vs. lifespan: New medicines to close the gap’ - a conference on ageing, which aims to tackle one of the UK’s most pressing healthcare challenges.
Drug Patent Watch
MAY 16, 2022
Annual Drug Patent Expirations for ESBRIET Esbriet is a drug marketed by Genentech Inc and is included in two NDAs. It is available from one supplier. There are twenty-one patents…. The post New patent for Genentech Inc drug ESBRIET appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
MAY 13, 2022
Today’s guest post comes from Shawn Seamans, Chief Commercial Officer at CoverMyMeds. Shawn discusses the unique challenges cancer patients face in accessing, affording, and adhering to treatment. He explains how patient-centric technology, combined with access to caring experts, can alleviate these challenges. Read more about access, affordability, and adherence opportunities for oncology patients in the CoverMyMeds 2022 Medication Access Report: Oncology Edition.
The Pharma Data
MAY 31, 2022
Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap and tools to improve approvability, accessibility, acceptability and affordability (4As) of biosimilars Sandoz launched initiative to support improved healthcare access, equity and sustainability.
Advarra
MAY 25, 2022
Compliant, efficient document management during the various phases of a clinical trial is essential. Yet, throughout a trial, as documents are added to different systems for the investigator/institution and the sponsor, a great deal of time is spent managing those documents; and, of course, as with any manual process, there’s risk of error. That’s why direct communication and integration between key technology systems like email, electronic institutional review board (eIRB) systems, clinical tri
Olympian Clinical Research
MAY 24, 2022
May is Mental Health Awareness Month , so there’s no better time to focus on our mental health and well-being. Good mental health is essential to our overall well-being and happiness, so it’s essential to do what we can to maintain it. To honor Mental Health Awareness Month, we have come up with a list of tips to help our patients and community members like you keep their mental health in optimal shape. 1.
Drug Discovery Today
MAY 10, 2022
IP covers novel method for assembly and error removal in DNA synthesis on silicon chips.
Drug Patent Watch
MAY 17, 2022
Annual Drug Patent Expirations for ZURAMPIC Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are nine patents protecting this drug. This drug…. The post New patent for Ironwood Pharms drug ZURAMPIC appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
MAY 10, 2022
Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB. You can find links to each company’s data below. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021.
The Pharma Data
MAY 31, 2022
FDA accepts Dupixent ® (dupilumab) for priority review in adult s with prurigo nodularis. Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved Acceptance marks another important step in advancing Dupixent for a broad range of diseases with underlying type 2 inflammation. The U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to
Crown Bioscience
MAY 16, 2022
In this blog we explore how drug efficacy studies can incorporate highly comprehensive morphology readouts that extend beyond cell viability assessments by leveraging high content screening (HCS), high content imaging (HCI), and high content analysis (HCA).
EG Life Sciences
MAY 12, 2022
As we have provided several blog posts and hosted Lean Coffees about the potential of Agile in Biopharma, a theme has emerged – the crucial role of communication in implementing Agile. We have discussed how to work with individual team members, from scientists who may be skeptical of Agile practices , to team members who are feeling "transparency anxiety," to leaders who haven't entirely bought in to the project.
Sygnature Discovery
MAY 9, 2022
Sygnature are thrilled to announce that we have embarked on a 3-year collaboration agreement with Iktos , an innovative technology company specialising in Artificial Intelligence (AI) for new drug design. We’ll be deploying Makya™ to facilitate rapid and efficient design of novel compounds and accelerate hit-to-lead/lead optimisation, further optimizing our integrated drug discovery capabilities and improving on how we serve our customers.
Drug Patent Watch
MAY 30, 2022
Annual Drug Patent Expirations for VIMOVO Vimovo is a drug marketed by Horizon and is included in one NDA. It is available from one supplier. There are nine patents protecting…. The post New patent expiration for Horizon drug VIMOVO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
MAY 30, 2022
Summer unofficially began over the weekend. Let’s turn up the heat with these sizzling news bites straight from the Drug Channels grill: SaveonSP gets sued Thoughts on the Medicaid accumulator rule opinion CVS buys AmerisourceBergen’s specialty pharmacy Fresh data on hospitals’ cancer drug profiteering Plus, Dr. Glaucomflecken explains Aetna’s prior authorization policies.
The Pharma Data
MAY 31, 2022
Initiation of global non-interventional study for patients with Parkinson’s planned for the second half of 2022 as next step. BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer?AG, announced?the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD).
The ChEMBL-og
MAY 5, 2022
UniChem new beta interface and web services We are excited to announce that our UniChem beta site will become the default one on the 11th of May. The new system will allow us to better maintain UniChem and to bring new functionality in a more sustainable way. The current interface and web services will still be reachable for a period of time at [link].
Expert insights. Personalized for you.
113 
Let's personalize your content